Germany's statutory insurers exclude weight-loss drugs as lifestyle drugs

German statutory health insurance, which covers about 90 percent of the population, does not reimburse drugs whose main purpose is weight reduction. The rule comes from the Social Code Book V (the law governing public health insurance), which lists such products as so-called lifestyle drugs, alongside medicines for appetite control or improving quality of life rather than treating illness.

In practice, this meant that newer injectable obesity treatments, such as semaglutide and similar GLP-1 drugs sold for weight loss, were not paid for by the public funds. Patients who wanted them had to cover the cost privately, often several hundred euros a month. The same active substances could be reimbursed when prescribed for type 2 diabetes, which led to debate over off-label use and supply shortages.

The exclusion mattered because obesity is widely recognised as a chronic condition linked to diabetes and heart disease. Doctors, patient groups and some politicians argued that the ban was outdated, while insurers pointed to the high cost of covering millions of potentially eligible people. The Federal Joint Committee (the body setting benefit rules) and lawmakers were therefore pushed to reconsider the rule.